Icatibant Acetate
Cardiovascular & vascular
The strongest research is acute hereditary angioedema (HAE).
An authorisation applies to at least one defined finished product in a stated jurisdiction; it does not apply automatically to this catalogue material.
What is Icatibant Acetate?
Icatibant acetate is a synthetic decapeptide antagonist of the bradykinin B2 receptor used in cardiovascular and angioedema research; the catalogue item denotes the acetate salt supplied for laboratory investigation.
Which research context has Icatibant Acetate been associated with?
Icatibant Acetate is associated with cardiovascular and vascular research as a synthetic bradykinin B2 receptor antagonist peptide, with strongest clinical research in acute hereditary angioedema and related bradykinin mediated pathophysiology studies.
What documentation is available for Icatibant Acetate?
Icatibant Acetate: Batch documents are not yet linked on this site. Required evidence for this synthetic bradykinin B2 antagonist peptide includes batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence confirmation; analytical HPLC/UPLC chromatogram with method and declared purity; peptide content, counterion and residual solvent/water declaration; and assay/potency data used for release testing. No batch documentation is shown as available until the record for that specific item is linked and reviewed.
What determines the storage conditions for Icatibant Acetate?
Icatibant Acetate: Storage depends on the documented supplied presentation; as a synthetic bradykinin B2 antagonist peptide verify dry/lyophilised versus solution supply, counterion and concentration, solvent or buffer choice, pH sensitivity, container closure compatibility and freeze/thaw behaviour since these impact peptide integrity and aggregation. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.